By Kounteya Sinha
New Delhi
Country, China Account For 50% Of Disease
Drug-resistant TB Sweeps IndiaAccording to WHO’s global report on drug-resistant TB released on Friday, an estimated 4.4 lakh people globally got infected with MDR TB in 2008 while 1.5 lakh died of it. Worldwide, there were an estimated 9.4 million cases of new TB cases in 2008 with 1.8 million deaths.
India estimates that 3% of all new TB cases in the country can’t be treated with standard drug regimens. Worldwide, of those patients receiving treatment, 60% were cured. However, only an estimated 7% of all MDR-TB patients are diagnosed.
MDR TB has several issues that can prove highly problematic for India. As against the 6-month treatment regimen for normal TB, MDR TB treatment can take up to two years or more to treat with drugs that are less potent and more toxic.
Moreover, medicines for drug-resistant TB are highly expensive. While a course of standard TB drugs costs $20, MDR TB drugs can cost up to $5,000.
The worst form of drugresistant TB—the extreme type referred to as XDR—is also raising its head much more frequently. WHO estimates there may be around 25,000 XDR TB cases a year with most proving fatal. Since XDR TB was first defined in 2006, a total of 58 countries have reported at least one case of this strain till 2008.
WHO also pointed to the fact that there was an urgent need to expand and accelerate diagnosis capabilities in countries and have technology that could diagnose MDR TB in two days rather than traditional methods which can take up to four months.
Drug-resistant TB usually arises when people are poorly treated or take substandard medicines. Not all countries have the surveillance systems to pick up cases of XDR TB.
Medical Menace
3% of all new TB cases in India can’t be treated with standard drug regimens While normal TB can be treated in 6 months, multi-drug resistant TB takes over 2 yrs with drugs less potent and more toxic Standard TB drugs cost $20; MDR TB medicines cost up to $5,000
Disclaimer: The news story on this page is the copyright of the cited publication. This has been reproduced here for visitors to review, comment on and discuss. This is in keeping with the principle of ‘Fair dealing’ or ‘Fair use’. Visitors may click on the publication name, in the news story, to visit the original article as it appears on the publication’s website.
